Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ajem.2021.05.054 http://scihub22266oqcxt.onion/10.1016/j.ajem.2021.05.054 34062319!8143907!34062319     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Emerg+Med 2021 ; 49 (ä): 58-61 Nephropedia Template TP {{tp|p=34062319|t=2021. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines |pdf=|usr=}}{{34062319}} gab.com Text Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines JO: Am J Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=34062319 #FOAvip BACKGROUND: Current vaccines for the Coronavirus Disease of 2019 (COVID-19) have demonstrated efficacy with low risk of adverse events. However, recent reports of thrombosis with thrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines have raised concern. OBJECTIVE: This narrative review summarizes the current background, evaluation, and management of TTS for emergency clinicians. DISCUSSION: TTS, also known as vaccine-induced immune thrombotic thrombocytopenia, is a reaction associated with exposure to the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and AD26.COV2.S (Johnson & Johnson) vaccine, which may result in thrombocytopenia and thrombotic events. There are several case series of patients diagnosed with TTS, but the overall incidence is rare. TTS is characterized by exposure to one of the aforementioned vaccines 4-30 days prior to presentation, followed by thrombosis, mild-to-severe thrombocytopenia, and a positive platelet factor-4 (PF4)-heparin enzyme-linked immunosorbent assay (ELISA). Thrombosis typically involves atypical locations, including cerebral venous thrombosis and splanchnic vein thrombosis. Evaluation should include complete blood count, peripheral smear, D-dimer, fibrinogen, coagulation panel, renal and liver function, and electrolytes, as well as PF4-heparin ELISA if available. Consultation with hematology is recommended if suspected or confirmed. Treatment may include intravenous immunoglobulin and anticoagulation, while avoiding heparin-based agents and platelet transfusion. CONCLUSIONS: With increasing vaccine distribution, it is essential for emergency clinicians to be aware of the evaluation and management of this condition. Twit Text FOAVip Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines ????Am J Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=34062319 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34062319 #FOAvip English Wikipedia <ref>{{Cite pmid|34062319}}</ref> Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines #MMPMID34062319 Long B; Bridwell R; Gottlieb M Am J Emerg Med 2021[Nov]; 49 (ä): 58-61 PMID34062319show ga BACKGROUND: Current vaccines for the Coronavirus Disease of 2019 (COVID-19) have demonstrated efficacy with low risk of adverse events. However, recent reports of thrombosis with thrombocytopenia syndrome (TTS) associated with adenovirus vector vaccines have raised concern. OBJECTIVE: This narrative review summarizes the current background, evaluation, and management of TTS for emergency clinicians. DISCUSSION: TTS, also known as vaccine-induced immune thrombotic thrombocytopenia, is a reaction associated with exposure to the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and AD26.COV2.S (Johnson & Johnson) vaccine, which may result in thrombocytopenia and thrombotic events. There are several case series of patients diagnosed with TTS, but the overall incidence is rare. TTS is characterized by exposure to one of the aforementioned vaccines 4-30 days prior to presentation, followed by thrombosis, mild-to-severe thrombocytopenia, and a positive platelet factor-4 (PF4)-heparin enzyme-linked immunosorbent assay (ELISA). Thrombosis typically involves atypical locations, including cerebral venous thrombosis and splanchnic vein thrombosis. Evaluation should include complete blood count, peripheral smear, D-dimer, fibrinogen, coagulation panel, renal and liver function, and electrolytes, as well as PF4-heparin ELISA if available. Consultation with hematology is recommended if suspected or confirmed. Treatment may include intravenous immunoglobulin and anticoagulation, while avoiding heparin-based agents and platelet transfusion. CONCLUSIONS: With increasing vaccine distribution, it is essential for emergency clinicians to be aware of the evaluation and management of this condition. |Ad26COVS1[MESH] |COVID-19 Vaccines/administration & dosage/*adverse effects[MESH] |COVID-19/epidemiology/*prevention & control[MESH] |ChAdOx1 nCoV-19[MESH] |Humans[MESH] |Syndrome[MESH] |Thrombocytopenia/*chemically induced/diagnosis/epidemiology[MESH] |Thrombosis/*chemically induced/diagnosis/epidemiology[MESH]Thrombosis with thrombocytopenia syndrome associated with COVID-19 vac(epmc).pdf DeepDyve Pubget Overpricing